Clinical trial · Interventional
A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer
A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 For Metastatic Breast Cancer.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
BZL 101 is an aqueous extract from herba Scutellaria Barbata D. Don of the Lamiaceae family. Preclinical studies suggest that this herb has antitumor activity for breast cancer and preliminary clinical data suggest that it is tolerable in patients with metastatic breast cancer. The overall goals of this Phase I/II trial are to assess the toxicity, maximum tolerated dose, safety and preliminary efficacy of BZL101 for the treatment of advanced metastatic breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BZL101 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Toxicity Based Upon Adverse Events Classifed by the NCI Common Terminology Criteria Version 3 (Phase 1)
- timeFrame
- Monthly
- description
- Dose-Limiting Toxicities graded according to Common Terminology Criteria for Adverse Events, version 3.0
- measure
- Response Evaluation Criteria In Solid Tumors (RECIST) (Phase 2)
- timeFrame
- 2 Months
- description
- Best Overall Tumor Response - Investigator Assessment
- measure
- Response Evaluation Criteria In Solid Tumors (RECIST) (Phase 2)
- timeFrame
- 2 months
- description
- Best Overall Tumor Response - Independent Radiology Assessment
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria: * Women 18 years or older * Histologically confirmed breast cancer * Clinical evidence of metastatic (stage IV) metastasis (other than bone metastasis) * Availability of estrogen and progesterone receptor status * At least one measurable disease site defined by RECIST criteria, 30 days prior to study therapy * For the phase 1, no more that 3 prior cytotoxic regimens for metastatic breast cancer. For the phase 2, no more than 2 prior cytotoxic regimens for metastatic breast cancer * Life expectancy ≥ 12 weeks * Eastern Cooperative Oncology Group performance status ≤2 * Women of child bearing potential must agree to 2 forms of contraception during the course of the trial. Key Exclusion Criteria: * Inability to understand/unwillingness to sign a written informed consent * Any significant side effects related to prior chemo, radiation, biology or hormonal therapy that did not resolve in the judgment of the investigator * Currently using an investigational agent * Clinically significant gastrointestinal abnormalities * Currently using coumadin at therapeutic doses or within 2 weeks of taking study medication * Concurrent palliative radiation or anti-cancer treatment * Women who report pregnancy, are breast-feeding or have a positive pregnancy test
References
Publications (1)
- RESULTPerez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat. 2010 Feb;120(1):111-8. doi: 10.1007/s10549-009-0678-5. PMID 20054647